According to The Paper, Meituan Health's express delivery and e-commerce business has welcomed another blockbuster new drug. On August 6th, the innovative anti-insomnia drug, Lebrexant, was first launched on Meituan. Lebrexant (Chinese brand name: Daweike) is the first approved dual orexin receptor antagonist, originally developed by Eisai Pharmaceuticals, for the treatment of adult insomnia characterized by difficulty falling asleep and/or maintaining sleep. It is not regulated as a psychotropic drug and has not been found to be addictive since its launch. Lebrexant is reportedly shown to shorten sleep onset, reduce nighttime awakenings, and prolong total sleep time. Furthermore, Lebrexant can prolong both non-rapid eye movement (NREM) and rapid eye movement (REM) sleep, helping to positively regulate sleep architecture and bring it closer to physiological sleep. Since last year, Meituan has launched seven new drugs, including Xingqi Atropine Sulfate 0.01% Eye Drops, Novowin, Novoxin, Telportide, Mastolide, Dotinol, and now Lebrexant.